TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.1 TWD | +0.78% |
|
0.00% | +9.88% |
| Sales 2024 * | 1.42B 43.95M | Sales 2025 * | 1.95B 60.15M | Capitalization | 24.6B 759M |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 7.47M | Net income 2025 * | 960M 29.63M | EV / Sales 2024 * | 16.7 x |
| Net cash position 2024 * | 824M 25.43M | Net cash position 2025 * | 1.79B 55.15M | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 * |
94.1
x | P/E ratio 2025 * |
23.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.78% | ||
| 1 month | +3.92% | ||
| 3 months | -6.92% | ||
| 6 months | +9.34% | ||
| Current year | +9.88% |
1 week
88.10
90.90
1 month
85.1091.50
Current year
81.70116.50
1 year
76.30122.00
3 years
52.20135.00
5 years
52.20172.50
10 years
1.05349.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chin-Ming Chang
CEO | Chief Executive Officer | - | - |
I Cheng Chen
DFI | Director of Finance/CFO | - | 08-05-31 |
Nien Yuan Chang
CHM | Chairman | - | 09-06-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi-Chuan Chen
BRD | Director/Board Member | 66 | - |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 18-09-06 |
Nien Yuan Chang
CHM | Chairman | - | 09-06-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +4.36% | - | |
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 90.1 | +0.78% | 1,018,374 |
| 24-06-06 | 89.4 | -1.00% | 495,688 |
| 24-06-05 | 90.3 | +0.89% | 546,971 |
| 24-06-04 | 89.5 | -0.11% | 451,900 |
| 24-06-03 | 89.6 | -0.55% | 452,476 |
End-of-day quote Taipei Exchange, June 06, 2024
More quotes
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
90.1
TWD
Average target price
137
TWD
Spread / Average Target
+52.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.88% | 758M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- 4147 Stock
